Trials / Recruiting
RecruitingNCT06903377
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZG005 for Injection | intravenous infusion |
| DRUG | Gecacitinib Hydrochloride Tablets | Oral |
Timeline
- Start date
- 2025-05-23
- Primary completion
- 2027-04-01
- Completion
- 2027-05-01
- First posted
- 2025-03-30
- Last updated
- 2026-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06903377. Inclusion in this directory is not an endorsement.